株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

次世代型がん診断の世界市場の分析と予測

Global Next Generation Cancer Diagnostics Market Research and Forecast, 2019-2025

発行 Orion Market Research Pvt Ltd 商品コード 801135
出版日 ページ情報 英文
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.21円で換算しております。
Back to Top
次世代型がん診断の世界市場の分析と予測 Global Next Generation Cancer Diagnostics Market Research and Forecast, 2019-2025
出版日: 2019年03月06日 ページ情報: 英文
概要

当レポートでは、世界の次世代型がん診断の市場の現状と見通しについて分析し、診断手法の概要や市場の基本構造、外部からのマクロ的・ミクロ的影響、主な促進・抑制要因、世界全体および地域別の市場動向の見通し (今後6年間分)、セグメント別 (技術、用途、エンドユーザーなど) の詳細動向、最新の市場競争状況、主要企業のプロファイルなどを調査しております。

第1章 分析概要

第2章 市場の概要と考察

  • 定義
  • アナリストの見解と現在の市場動向
    • 分析のポイント
    • 提言
    • 結論
  • 世界各国の規制・法令

第3章 競争環境

  • 企業戦略の一覧
  • 主要戦略の分析
  • 主要企業の分析
    • F. Hoffmann-La Roche Ltd
      • 概要
      • 財務分析
      • SWOT分析
      • 近年の動向
    • General Electric Co.
    • Illumina, Inc.
    • PerkinElmer Inc.
    • Thermo Fisher Scientific Inc.

第4章 市場の決定要因

  • 促進要因
  • 抑制要因
  • 市場機会

第5章 市場区分

  • 世界の次世代型がん診断市場:技術別
    • 次世代型シーケンシング
    • qPCR (定量ポリメラーゼ連鎖反応)、マルチプレクシング (多重化)
    • プロテインマイクロアレイ
    • DNAマイクロアレイ
    • その他 (ラブオンチップ、RT-PCR (逆転写PCR))
  • 世界の次世代型がん診断市場:用途別
    • バイオマーカー開発
    • プロテオミクス分析
    • がん検診
    • その他 (血中循環腫瘍細胞 (CTC) 分析)
  • 世界の次世代型がん診断市場:エンドユーザー別
    • 病院・診療所
    • 研究センター

第6章 地域別分析

  • 北米 (米国、カナダ)
  • 欧州 (英国、ドイツ、イタリア、スペイン、フランスなど)
  • アジア太平洋地域 (中国、インド、日本など)
  • 他の国々 (RoW)

第7章 企業プロファイル

  • Agilent Technologies, Inc.
  • Almac Group Ltd.
  • Biodesix, Inc.
  • Biospherex LLC
  • Cepheid
  • Cernostics, Inc.
  • F. Hoffmann-La Roche Ltd
  • General Electric Co.
  • Genomic Health, Inc.
  • Illumina, Inc.
  • Lunaphore Technologies S.A.
  • Metabiomics Corp.
  • Myriad Genetics, Inc.
  • Novartis International AG
  • OPKO Health Inc.
  • PerkinElmer Inc.
  • Personalis Inc.
  • QIAGEN N.V.
  • シスメックス
  • Thermo Fisher Scientific Inc.
図表

List of Tables

  • 1. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2018-2025 ($ MILLION)
  • 2. GLOBAL NEXT GENERATION SEQUENCING MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 3. GLOBAL QPCR & MULTIPLEXING MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 4. GLOBAL PROTEIN MICROARRAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 5. GLOBAL DNA MICROARRAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 6. GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 7. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2018-2025 ($ MILLION)
  • 8. GLOBAL BIOMARKER DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 9. GLOBAL PROTEOMICS ANALYSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 10. GLOBAL CANCER SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 11. GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 12. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)
  • 13. GLOBAL HOSPITALS & CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 14. GLOBAL RESEARCH CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 15. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
  • 16. NORTH AMERICAN NEXT GENERATION CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 17. NORTH AMERICAN NEXT GENERATION CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2018-2025 ($ MILLION)
  • 18. NORTH AMERICAN NEXT GENERATION CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2018-2025 ($ MILLION)
  • 19. NORTH AMERICAN NEXT GENERATION CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)
  • 20. EUROPEAN NEXT GENERATION CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 21. EUROPEAN NEXT GENERATION CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2018-2025 ($ MILLION)
  • 22. EUROPEAN NEXT GENERATION CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2018-2025 ($ MILLION)
  • 23. EUROPEAN NEXT GENERATION CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)
  • 24. ASIA-PACIFIC NEXT GENERATION CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 25. ASIA-PACIFIC NEXT GENERATION CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2018-2025 ($ MILLION)
  • 26. ASIA-PACIFIC NEXT GENERATION CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2018-2025 ($ MILLION)
  • 27. ASIA-PACIFIC NEXT GENERATION CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)
  • 28. REST OF THE WORLD NEXT GENERATION CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2018-2025 ($ MILLION)
  • 29. REST OF THE WORLD NEXT GENERATION CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2018-2025 ($ MILLION)
  • 30. REST OF THE WORLD NEXT GENERATION CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)

List of Figures

  • 1. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SHARE BY TECHNOLOGY, 2018 VS 2025 (%)
  • 2. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SHARE BY APPLICATION, 2018 VS 2025 (%)
  • 3. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SHARE BY END-USERS, 2018 VS 2025 (%)
  • 4. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
  • 5. US NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 6. CANADA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 7. UK NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 8. FRANCE NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 9. GERMANY NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 10. ITALY NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 11. SPAIN NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 12. ROE NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 13. INDIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 14. CHINA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 15. JAPAN NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 16. REST OF ASIA-PACIFIC NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 17. REST OF THE WORLD NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2025 ($ MILLION)
目次
Product Code: OMR2019591

Global Next Generation Cancer Diagnostics Market Size, Share & Trends Analysis Report by Technology (Next Generation Sequencing, QPCR & Multiplexing, Protein Microarrays, DNA Microarrays, and Others), by Application (Biomarker Development, Proteomic Analysis, Cancer Screening, and Others) by End-User (Hospital & Clinics, and Research Centers), and Forecast, 2019-2025

Next generation cancer diagnostics technology offers potential in the discovery of advanced actionable targets for cancer. This technique is more sensitive and provides effective diagnostic solutions in cancer as compared to Sanger sequencing. In the next generation sequencing, multiple anomalies consisting of different genomic scales can be assayed simultaneously. The technology is actively used in various applications, including proteomic analysis, cancer screening, and biomarker development, among others.

Increase in government initiatives for the development of advanced technologies in cancer diagnostics is driving the growth of the market. The rising prevalence of cancer disorders across the globe is offering a growth opportunity for the market. According to the National Cancer Institute (the US), in 2018, around 2 million cases of cancer were diagnosed in the US, among which, nearly 609,640 mortality cases were estimated in the country due to cancer. The rising development of advanced next-generation cancer diagnostic technologies is expected to cater to the increasing number of cancer patients across the globe.

Global next generation cancer diagnostics market is further analyzed on the basis of geography, including North America, Europe, Asia-Pacific, and Rest of the World. North America contributed the largest share in the global next-generation cancer diagnostics market in 2018. This is mainly owing to the increasing prevalence of cancer in the region, owing to which, there are favorable investments being provided by the government for the development of advanced diagnostics and therapeutics. Asia-Pacific is projected to exhibit the fastest growth in the global next-generation cancer diagnostics market during the forecast period. The rising medical tourism and increasing focus on the establishment of advanced healthcare infrastructure in emerging economies such as India and China are some factors that are propelling the market growth in the region.

Major market players operating in the global next-generation cancer diagnostics market include Agilent Technologies, Inc., Biospherex LLC, F. Hoffmann-La Roche Ltd, General Electric Co., Illumina, Inc., Novartis AG, and PerkinElmer Inc., among others. These companies adopt various strategies such as geographical expansion, merger & acquisition, partnership & collaborations, finding a new market or innovations in their core competency in order to stay competitive in the market.

Research Methodology

The market study of the global next-generation cancer diagnostics market is incorporated by extensive primary and secondary research conducted by a research team at OMR. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market
  • Authentic Public Databases such as National Center for Biotechnology Information (NCBI)
  • Whitepapers, research-papers and news blogs
  • Company websites and their product catalog.

The report is intended for biotechnology companies, research organizations, investment companies, government organizations for overall market analysis and competitive analysis. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.

Market Segmentation:

  • 1. Global Next Generation Cancer Diagnostics Market Research and Analysis by Technology
  • 2. Global Next Generation Cancer Diagnostics Market Research and Analysis by Application
  • 3. Global Next Generation Cancer Diagnostics Market Research and Analysis by End-User

The Report Covers:

  • Comprehensive research methodology of the global next-generation cancer diagnostics market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global next-generation cancer diagnostics market.
  • Insights about market determinants which are stimulating the global next-generation cancer diagnostics market.
  • Detailed and extensive market segments with regional distribution of forecast revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography
    • 1.2.3. By Stakeholders

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Competitive Dashboard
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. F. Hoffmann-La Roche Ltd
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. General Electric Co.
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Illumina, Inc.
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. PerkinElmer Inc.
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Thermo Fisher Scientific Inc.
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Next Generation Cancer Diagnostics Market by Technology
    • 5.1.1. Next Generation Sequencing
    • 5.1.2. QPCR & Multiplexing
    • 5.1.3. Protein Microarrays
    • 5.1.4. DNA Microarrays
    • 5.1.5. Others (Lab-on- a- chip & Reverse Transcriptase-PCR (RT-PCR))
  • 5.2. Global Next Generation Cancer Diagnostics Market by Application
    • 5.2.1. Biomarker Development
    • 5.2.2. Proteomic Analysis
    • 5.2.3. Cancer Screening
    • 5.2.4. Others (CTC Analysis)
  • 5.3. Global Next Generation Cancer Diagnostics Market by End-User
    • 5.3.1. Hospitals & Clinics
    • 5.3.2. Research Centers

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Agilent Technologies, Inc.
  • 7.2. Almac Group Ltd.
  • 7.3. Biodesix, Inc.
  • 7.4. Biospherex LLC
  • 7.5. Cepheid
  • 7.6. Cernostics, Inc.
  • 7.7. F. Hoffmann-La Roche Ltd
  • 7.8. General Electric Co.
  • 7.9. Genomic Health, Inc.
  • 7.10. Illumina, Inc.
  • 7.11. Lunaphore Technologies S.A.
  • 7.12. Metabiomics Corp.
  • 7.13. Myriad Genetics, Inc.
  • 7.14. Novartis International AG
  • 7.15. OPKO Health Inc.
  • 7.16. PerkinElmer Inc.
  • 7.17. Personalis Inc.
  • 7.18. QIAGEN N.V.
  • 7.19. Sysmex Corp.
  • 7.20. Thermo Fisher Scientific Inc.
Back to Top